Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

InterSystems and Inspur Enter Agreement to Innovate Healthcare Big Data Platforms in China

InterSystems and Inspur Enter Agreement to Innovate Healthcare Big Data Platforms in China

InterSystems, a global leader in information technology platforms for health, business, and government applications, announced an agreement for strategic cooperation, signed at its recent Global Summit, with leading Chinese cloud computing and big data service provider, Inspur. Inspur will implement its healthcare big data platform using the InterSystems IRIS for Health™ data platform, and the companies will jointly promote the innovation and application of healthcare big data platforms, accelerate the sharing of healthcare big data, and integrate artificial intelligence (AI) technology.

Inspur is committed to helping governments, individuals, medical institutions, and application developers build data-centric technology platforms and working with partners to create an ecosystem facilitating data socialization – making data and data analytics tools easily accessible. Inspur is one of the few enterprises that construct and operate healthcare big data platforms in China, and has been recognized for its successful outcomes. Its healthcare big data platforms support unified management of health data, as well as data sharing among organizations based on data and safety standards, and quality control, which is critical to unlocking its full value.

“We are excited to enter into an agreement for strategic cooperation with InterSystems,” said Chuangui Gao, Vice President of Inspur Group. “InterSystems’ advanced technologies empower healthcare organizations and regional health management systems worldwide to innovate and transform by enabling fast systems development and deployment, as well as data interoperability.”

Inspur will implement InterSystems IRIS as a high-performance data platform providing data lifecycle management, interoperability, transaction processing, and analytics. It will take advantage of IRIS for Health’s pre-built models for data transformation and native support for FHIR, allowing different health data platforms to rapidly ingest, normalize, and share information for consistent insight into large amounts of health data. “InterSystems IRIS also provides an open environment, supporting a wide range of customer environments and application requirements,” said Chuangui Gao.

In February, InterSystems and Inspur undertook innovative research and pilot projects for big data platform technologies using the InterSystems HealthShare Health Connect integration platform and IRIS for Health. The goal is to utilize world leading technology and experience to further develop these advanced technologies, and to incorporate international medical data standards and innovation in accordance with Chinese security frameworks and safety standards for application solutions. With InterSystems, Inspur aims to empower large medical institutions and regional health information platforms, based on global experience in data management, to accelerate the innovative application of big data interoperability and AI, for example, for disease forecasting and population health. Not only will this benefit patients and care providers, but it will also promote new business models and sources of economic growth.

“We are delighted to work with Inspur to boost Chinese healthcare innovation and development, and the application of healthcare big data platforms,” said Luciano Brustia, Regional Managing Director, Asia Pacific. “InterSystems values the Chinese market and has partnered with organizations here for more than 20 years. The Chinese economy continues to grow rapidly, the standard of living continues to improve, and the demand for healthcare services continues to increase, leading to unprecedented growth in the healthcare industry.”

“InterSystems is honored to be chosen by Inspur as a partner,” said Paul Grabscheid, Vice President, Strategic Planning for InterSystems. “We are committed to the continued introduction of advanced technologies in China and we will do what we can to support the healthcare industry now and in the future.”

About Inspur
Inspur is China’s leading cloud computing, big data service provider with four listed companies: Inspur Information, Inspur Software, Inspur International and Inspur Huaguang, covering four major industry groups of cloud data center, cloud services & big data, smart city, and smart enterprises. Inspur offers IT products and services that satisfy the needs of governments and enterprises in more than 100 countries and regions. In 2018, Inspur identified a data-first strategy to build a platform-type ecosystem of enterprises based on the world’s leading cloud data center and cloud service platforms. Working hand in hand with partners, Inspur will facilitate socialization of data and accelerate its pace in transforming into a “new operator” of cloud service, big data, and smart city. The goal is to become a new Internet company that integrates “cloud, data and AI”.

About InterSystems
InterSystems is the information engine that powers some of the world’s most important applications. In healthcare, business, government, and other sectors where lives and livelihoods are at stake, InterSystems has been a strategic technology provider since 1978. InterSystems is a privately held company headquartered in Cambridge, Massachusetts (USA), with offices worldwide, and its software products are used daily by millions of people in more than 80 countries. For more information, please visit http://www.intersystems.com/

Hospitals Share Digital Transformation Experiences at InterSystems Asia Pacific Healthcare Customer Meeting

InterSystems Asia Pacific Healthcare Customer Meeting

Hospitals across the region have come together to share their digital transformation experiences at the first annual Healthcare Asia Pacific Customer Meeting held by InterSystems, a global leader in information technology platforms for health, business and government.

Over 100 delegates from more than 30 hospitals in China, Indonesia, Thailand, Malaysia, Australia, and New Zealand heard from some of the most technologically advanced healthcare providers in the region about their use of new digital capabilities including big data analysis, predictive analytics, artificial intelligence (AI), and machine learning.

Leading hospitals revealed how they were using advanced technologies to support transformational changes such as population health and value-based care initiatives. The Bangkok event – with a theme of “creating the future of care” – also outlined strategies to mitigate clinical safety and cyber security risks.

At the same event, attendees learned about the latest interoperability, mobility and advanced clinical technologies from InterSystems, as well as strategies to improve clinician electronic medical record (EMR) system satisfaction and adoption from healthcare IT data and insights analyst firm KLAS Research.

Healthcare Unbounded
In his opening remarks, Luciano Brustia, Regional Managing Director – Asia Pacific for InterSystems, said that despite all the innovations, breakthroughs, and increases in life expectancy, healthcare systems are still full of information silos and barriers between different people, processes, and organizations. In fact a new survey by InterSystems showed that 55% of private hospitals in South East Asia see system interoperability challenges as a barrier to digital transformation.

“Along with our customers and partners, InterSystems is creating the future of care, something we call Healthcare Unbounded, where all the different care givers are empowered with a complete and easy-to-use picture of each patient and are coordinated with each other,” said Brustia. “Advanced interoperability using standards like FHIR will extend the EMR to collect information that wasn’t available to caregivers in the past. And healthcare providers will understand their populations better, using data analytics and AI to predict healthcare risks and develop new treatments based on what works and what doesn’t work in the real world.”

Using AI to make clinical predictions
Kenny Lim, CIO of Bumrungrad International Hospital in Bangkok and Eric Widen, Co-founder & CEO of HBI Solutions, revealed how Bumrungrad had used HBI’s Spotlight solution to analyze data in its InterSystems TrakCare® EMR and employ machine learning and AI technology. This enabled the hospital to make predictions about the onset of sepsis, the risk of mortality, length of hospital stay, and likelihood of patients developing chronic diseases.

Bumrungrad’s vision is to provide “world-class holistic healthcare by 2022”, said Lim, providing patients with care and treatments for both immediate health problems and overall wellbeing. According to the InterSystems survey, Bumrungrad is one of only 5% of private hospitals in South East Asia that have deployed AI, a figure expected to rise to 56% over the next five years.

Focusing on patient-centered, smart healthcare
Dr. Jenny Shao, Health Information Systems Director for United Family Healthcare in China, shared key learnings from UFH’s 11-year journey with TrakCare. UFH has already transformed from a clinician-centered to a patient-centered approach to care, and is currently transforming from a focus on the patient to a focus on the whole person.

Dr. Shao also previewed UFH’s next transformation to smart healthcare, smart hospital and community, applying technology to support “P4 healthcare” which was predictive, preventative, personalized, and participatory.

Mitigating safety and cyber security risks
While minimizing clinical risks is a key driver of digitization, delegates heard about strategies to mitigate the clinical safety and cyber security risks that also come with digital healthcare.

InterSystems Clinical Safety Managers from China, Thailand, and Australia/New Zealand spoke about the company’s clinical safety framework, which identifies and assesses risks and proactively takes action to mitigate them. Attendees learned about how they could become personally involved in patient safety initiatives at their own hospitals and partner with InterSystems to further improve patient safety for all TrakCare EMR users.

According to Ken Mortensen, Data Protection Officer for InterSystems, systems interoperability and the cloud have created a bigger attack surface for hackers. However, the cloud now also enables healthcare providers to centralize security controls to increase systems security. Mortensen recommended a readiness assessment to better understand the cyber threats healthcare providers face and to assess whether hospitals have the right security measures in place to deal with them and whether staff are properly trained about privacy and security.

Mobility and TrakCare Open Access
Delegates learned about the expanded capabilities of the latest version of TrakCare, built on the InterSystems IRIS for Health™ data platform, and how IRIS has boosted systems interoperability, cloud scalability and healthcare big data capabilities. They also heard how mobility is improving the user experience wherever care is delivered.

Dimitri Fane, Director of Product Management for TrakCare, demonstrated how the product’s mobile-enabled user interface supports all clinical workflows, including operating theatre bookings and administration, maternity and nursing care plans, dynamic patient lists, and a patient journey tracker.

InterSystems also introduced Asia Pacific customers to TrakCare Open Access, enabling them to develop or deploy solutions based on the SMART on FHIR standard. “We are actively seeking Asia Pacific customers to partner with us around SMART on FHIR to innovate and enhance the TrakCare experience to take full advantage of their EMR data,” said Fane.

About InterSystems
InterSystems is the information engine that powers some of the world’s most important applications. In healthcare, business, government, and other sectors where lives and livelihoods are at stake, InterSystems has been a strategic technology provider since 1978. InterSystems is a privately held company headquartered in Cambridge, Massachusetts (USA), with offices worldwide, and its software products are used daily by millions of people in more than 80 countries. For more information, please visit http://www.intersystems.com/

 

Innovia Medical Announces Acquisition of DTR Medical

Innovia Medical Announces Acquisition of DTR Medical

Innovia Medical announced its partnership with DTR Medical. Based in Swansea, Wales, United Kingdom, DTR Medical specialises in the design and manufacture of single-use surgical instruments for general and specialist surgical procedures.

“Since their founding in 2005, DTR Medical have established themselves as a multi-award winning manufacturer of quality and innovative single-use instruments. Exporting to over 30 countries they have built their reputation on consistently high product quality alongside their exceptional customer service.” Terry Meredith, Chief Executive Officer of Innovia Medical.

“The strategic acquisition of DTR Medical will further strengthen Innovia’s global position in the ENT and Ophthalmic market; in addition, providing new opportunities in areas such as Gynaecology and General Surgery.”

Flagship products include the Rotating Biopsy Punch, Frazier Suction Handle, Tibbs Arterial Cannula and Ear Specula.

“We are excited to be partnering with Innovia Medical as this investment will allow us to continue to develop our innovative surgical solutions, whilst bringing our products to a wider global audience.” Andrew Davidson, Managing Director of DTR Medical

“The team at DTR Medical are dedicated to providing outstanding customer service, alongside high quality products that deliver clinical value and improved patient outcomes. It was important for us to find a partner who shared and respected the same core values, whilst providing the opportunity to take our vision to new markets.” Richard Salvage, Founder DTR Medical

About Innovia Medical

Innovia Medical is a family of specialty surgical companies that are passionately committed to partnering with medical professionals to help elevate the delivery of patient care and improve clinical outcomes.

Innovia Medical companies develop and manufacture solutions that save time for both the medical professional and patient, delivers a consistent and predictable care experience, and improves patient confidence with reduced recovery times and less discomfort.

Community Health Systems Announces Definitive Agreements to Sell Three Virginia Hospitals

Community Health Systems Announces Definitive Agreements to Sell Three Virginia Hospitals

Community Health Systems, Inc announced that affiliates of the Company have signed a definitive agreement to sell three Virginia hospitals – 300-bed Southside Regional Medical Center in Petersburg, 105-bed Southampton Memorial Hospital in Franklin and 80-bed Southern Virginia Regional Medical Center in Emporia, and their associated assets to subsidiaries of Bon Secours Mercy Health, Inc. The transaction is expected to close by the end of 2019, subject to customary regulatory approvals and closing conditions.

About Community Health Systems, Inc.

Community Health Systems, Inc. is one of the largest publicly traded hospital companies in the United States and a leading operator of general acute care hospitals in communities across the country. The Company, through its subsidiaries, owns, leases or operates 102 affiliated hospitals in 18 states with an aggregate of approximately 17,000 licensed beds.

The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” More information about the Company can be found on its website at www.chs.net

STEM Healthcare appoints Daisaburo Sakurai as Senior Vice President and Representative Director of Japan

STEM Healthcare appoints Daisaburo Sakurai as Senior Vice President and Representative Director of Japan

Global benchmarking company STEM Healthcare (STEM) is pleased to announce the appointment of Daisaburo Sakurai as Senior Vice President and Representative Director of Japan effective 1st September 2019.

Daisaburo brings 24 years of experience in the global pharmaceutical industry. Daisaburo joins STEM from Biogen where he was the Director, head of the Neurology Business Unit in Japan. In that role, he tripled his business within 4 years through a successful new product launch, organizational structure changes and strategic partnership development. Prior to Biogen, Daisaburo was at Bayer and had several leadership positions in Japan and Canada.

Daisaburo holds an MBA from the Rotman School of Management, University of Toronto.

Commenting on his new role, Daisaburo said, “It is a privilege to be joining STEM as the Senior Vice President and Representative Director in Japan at such an exciting time. I am thrilled to work with STEM’s innovative and talented team as we work for helping Pharma companies to accelerate their performance. I am sure that we will become the best partner for them, and developing the ‘new era’ of STEM in Japan with a sustainable growth.”

Daisaburo will report to Laurence Bannister (President, STEM International).

Laurence said “I am very excited to warmly welcome Daisaburo to STEM. His experience, track record of success, leadership skills and energy will be key to drive further growth in this critically important market. I very much look forward to working with Daisaburo and seeing the Japanese business grow under his leadership.”

About STEM® Healthcare

STEM is a global benchmarking company that partners with 29 of the top 30 pharmaceutical companies to further accelerate performance. Working with commercial, field medical, market access and account management teams, STEM has built an industry leading benchmark database based on more than 300,000 in field observations. STEM has 7 offices globally and capabilities in >40 countries. In 2016, STEM received the prestigious Queen’s Award for Enterprise recognizing the contribution to international trade. STEM is part of Ashfield Advisory, a UDG Healthcare company. For further information visit our website at www.stemhealthcare.com

InterSystems Survey Finds Asian Private Hospitals Expanding Digital Capabilities to Support Patient-focused Transformation

Private hospitals in South East Asia will dramatically expand the capabilities of their healthcare information systems over the next five years to support transformational changes such as value-based care initiatives and better care coordination, according to a survey by InterSystems, a global leader in information technology platforms for health, business and government.

“Private hospitals in South East Asia operate in a highly competitive environment where they need to differentiate themselves to attract patients with high expectations and wanting the best clinical care,” said Kerry Stratton, Managing Director, South East Asia at InterSystems.

“With digital transformation private hospitals can innovate and stand out from the competition by providing a superior patient experience and the highest levels of clinical excellence.”

Survey Highlights

Drivers for Digital Transformation

  • Internal process efficiencies – 78%
  • The need to innovate – 75%
  • Patient expectations – 73%

Barriers to Digital Transformation

  • Change management challenges – 61%
  • System interoperability challenges – 55%
  • Lack of qualified staff – 45%

Changes in System Capabilities in 5 years

  • Real-time big data analysis – up from 13% to 69%
  • Artificial intelligence – up from 5% to 56%
  • Use of paper records – down from 56% to 6%

Transformational Changes in 5 years

  • Value-based care initiatives – up from 16% to 64%
  • Care coordination with outside organizations – up from 22% to 58%
  • Analysis of clinical information about groups of patients – up from 19% to 52%

New Digital Technology Capabilities
Many hospitals claim to be digital today, thanks to the adoption of electronic medical records (EMRs), which provide the foundation for digital transformation. But according to the InterSystems survey, Taking the Pulse of Digital Transformation in Healthcare – South East Asia, most Asian private hospitals are still in the process of phasing out paper records and need to make additional investments for data to flow across the continuum of health and care.

Private hospitals will almost completely end the use of paper-based records in favor of fully digital systems within five years, however. While 56% of survey respondents said they currently use paper-based records, the figure is expected to fall to only 6% of private hospitals in five years.

The move to the full digitization of health information will pave the way for a range of new digital technology capabilities. The survey found that most Asian private hospitals expect to implement real-time big data analysis capabilities over the next five years, with the proportion increasing from 13% of hospitals currently to 69% in five years.

Around half of private hospitals surveyed expect to implement artificial intelligence (AI) capabilities, with the figure rising from 5% currently to 56% in five years. Nearly half of private hospitals will implement support for remote patient monitoring systems (e.g. in-home devices), with the percentage increasing from 6% currently to 53% in five years.

Transformational Changes
The InterSystems survey found that new digital technology capabilities will enable many transformational changes at private hospitals. The biggest is expected to be a move to support value-based care initiatives – an alternative to fee-for-service reimbursement. Currently only 16% of Asian hospitals’ digital systems support value-based care initiatives, a figure expected to quadruple to 64% in five years.

The second-biggest change is expected to be supporting care coordination with outside organizations, rising from 22% currently to 58% in five years. The third was ability to analyze clinical information about groups (cohorts) of patients, increasing from 19% currently to 52% of private hospitals in five years. The fourth-biggest change was the ability to support patient wellness strategies, up from 36% currently to 63% in the same time period.

“The entire customer experience needs to be taken into account while planning a hospital’s digital transformation, and the good news is that this is starting to happen,” said Stratton. “The most common transformational changes that Asian private hospitals expect to make – whether improving the value they receive, better targeted treatments, improved care coordination, or wellness strategies – all have a strong focus on the patient.”

To create the survey, 70 senior executives were polled at 28 leading private hospitals across Asian countries including Indonesia, Malaysia, the Philippines and Thailand. You can download the full Taking the Pulse of Digital Transformation in Healthcare – South East Asia survey report here

About InterSystems
InterSystems is the information engine that powers some of the world’s most important applications. In healthcare, business, government, and other sectors where lives and livelihoods are at stake, InterSystems has been a strategic technology provider since 1978. InterSystems is a privately held company headquartered in Cambridge, Massachusetts (USA), with offices worldwide, and its software products are used daily by millions of people in more than 80 countries. For more information, please visit http://www.intersystems.com/.

AliveCor and Huami Partner To Deliver The Next Generation of Medical Wearables

AliveCor and Huami Partner To Deliver The Next Generation of Medical Wearables

AliveCor, the leader in AI based, personal ECG technology, and provider of enterprise cardiology solutions; and Huami Corporation, a global leader in biometric, data-driven wearables, announced a multi-faceted global strategic alliance that combines the technologies of each company to deliver a new generation of medical functionality to wearable devices.

“AliveCor’s Intelligent, medical grade, heart care platform will be a key component of Huami smart watches and heart trackers going forward. Our new partnership is critical to building these as well as entirely new medical grade services,” said Wang Huang, CEO of Huami.

“AliveCor’s agreement with Huami achieves our corporate goal of delivering AliveCor’s AI driven subscription services and solutions to enterprise customers and consumers worldwide at affordable price points. AliveCor technology allows partners to easily deliver clinically validated, peer-reviewed medical features to their own customers, at scale,” said AliveCor CEO Priya Abani.

The agreement announced today encompasses the licensing of AliveCor technology and an agreement to work together to bring new devices and services to market. The companies expect that the alliance will deliver entirely new ECG form factors to global markets in 2020.

About Huami Corporation

Huami is a biometric and activity data-driven company with significant expertise in smart wearable technology. Since its inception in 2013, Huami has quickly established its global market leadership and recognition by shipping millions of units of smart wearable devices. In 2018, Huami shipped 27.5 million units of smart wearable devices. Huami has one of the largest biometric and activity databases in the global smart wearables industry. Huami’s mobile apps work hand in hand with its smart wearable devices and provide users with a comprehensive view and analysis of their biometric and activity data.

About AliveCor

AliveCor, Inc. is transforming cardiological care using deep learning. The FDA-cleared KardiaMobile is the most clinically validated personal ECG solution in the world. KardiaMobile provides instant detection of Atrial Fibrillation, Bradycardia, Tachycardia, and Normal rhythm in an ECG. Kardia is the first AI enabled platform to aid patients and clinicians in the early detection of atrial fibrillation, the most common arrhythmia and one associated with a five times greater risk of stroke. AliveCor’s KardiaPro enterprise platform allows practitioners and institutions to manage chronic heart conditions simply and profitably using KardiaMobile. AliveCor was named the No.1 artificial intelligence company in Fast Company’s Top 50 Most Innovative Companies. AliveCor is a privately-held company headquartered in Mountain View, Calif. “Consumer” or “Personal” ECGs are ECG devices available for direct sale to consumers.

Sherlock Biosciences and Mologic Establish Strategic Partnership to Develop Instrument-free Molecular Diagnostic Tests

Instrument-free Molecular Diagnostic Tests

Sherlock Biosciences , an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, and Mologic Ltd, a leading developer of lateral flow and rapid diagnostic technologies, announced a new collaboration to revolutionize molecular diagnostic testing in low-resource settings and within the home.

The work is being facilitated by the Bill & Melinda Gates Foundation through an expansion of an existing grant to Mologic. Through the partnership, Mologic will expand its presence in Cambridge, Mass., as part of a joint development center that will be built within Sherlock’s lab space. The companies will combine Sherlock’s core synthetic biology platform with Mologic’s advanced lateral flow expertise to develop simple, sophisticated molecular diagnostics for use at the point of need.

Supporting endeavors to create a new field of molecular diagnostics and facilitate more targeted therapies, the funding from the Gates Foundation will bolster efforts to leverage Sherlock’s synthetic biology-based INSPECTRTM platform and Mologic’s core immunoassay platforms—ELTABA for enzyme activity detection, and CARD, the high sensitivity lateral flow technology developed at Mologic’s Centre for Advanced Rapid Diagnostics.

This work will advance affordable, universal detection platforms that will detect DNA or RNA targets in virtually any decentralized site, including low-resource settings and home-based testing. Mologic established its CARD platform with prior funding and support from the Gates Foundation.

This collaboration will enable Mologic to expand its presence in the U.S., where it has already established a New England subsidiary. By building out a joint development space with equipment and staff, Mologic will establish full immunoassay research and development capabilities and enhance its ability to provide service and support to its U.S.-based partners.

“Our INSPECTR platform was designed to be the very first low-cost, rapid, instrument-free molecular diagnostic system to truly address diagnostic needs where solutions do not exist today, especially in low-resource and home settings,” said Rahul K. Dhanda, Sherlock’s Co-Founder, President and Chief Executive Officer. “This program will enable us to build on the power of our INSPECTR platform to create diagnostic tools that provide accurate and affordable results in virtually any setting, while working with Mologic and the Bill & Melinda Gates Foundation to develop lateral flow technology to improve global health.”

“We believe there is a unique and powerful synergy between Mologic and Sherlock, and we are delighted to have the Gates Foundation support our efforts to combine our first- and best-in-class technology platforms for nucleic acid sensing, super-antibody engineering, ultra-sensitive lateral flow assays, and enzyme activity detection,” said Mark Davis, Mologic’s Chief Executive Officer and Co-Founder. “By leveraging both companies’ core technologies, we believe we can create extremely sensitive diagnostic tests that produce results with unprecedented speed, without requiring instrumentation, thermal amplification or electricity.”

About INSPECTR

Sherlock Biosciences’ INSPECTR™ (Internal Splint-Pairing Expression Cassette Translation Reaction) platform leverages the power of Synthetic Biology by using cell-free systems as programmable molecular diagnostic devices. INSPECTR enables the creation of instrument-free, simple-to-operate diagnostic tests that can be applied across multiple diseases and used in a variety of settings.

About ELTABA

Mologic’s patented enzymatic activity platform ELTABA (Enzymatic Ligand Transformation Affinity Binding Assay) enables highly specific and sensitive measurement of enzymes outside of the laboratory and in the hands of untrained users. The system works by detecting substrate cleavage sites with a specific antibody that is captured and developed in a traditional lateral flow immunoassay format. This technology enables amplification of signal and a more specific interaction compared to simple antigen detection.

About CARD

Mologic’s Centre for Advanced Rapid Diagnostics (CARD) was established in 2016 with support from the Bill & Melinda Gates Foundation to redefine and re-engineer the critical components of the lateral flow immunoassay. In 2018, CARD succeeded with the aim of developing a rapid, ultra-sensitive, visually read and electricity free detection platform. First demonstrated with malaria and HIV as exemplars, the step change improvements in lateral flow technology resulted from improvements to the engineering of super-antibodies, the deployment of a novel nanoparticle as an alternative to gold, and innovations in assay choreography and smart design. The CARD platform is now being deployed across Mologic’s internal portfolio and for external clients through its services division.

About Sherlock Biosciences

Sherlock Biosciences is dedicated to making molecular diagnostics better, faster and more affordable through Engineering Biology platforms. The company is developing applications of SHERLOCK™, a CRISPR-based method to detect and quantify specific genetic sequences, and INSPECTRTM, a Synthetic Biology-based molecular diagnostics platform that is instrument-free. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, opening up a wide range of potential applications in areas including precision oncology, infection identification, food safety, at-home tests and disease detection in the field. For more information visit Sherlock.bio.

About Mologic

Mologic is a leading developer of advanced lateral flow and rapid diagnostic technologies. Leveraging its core technology platforms, the Company works with global organizations, researchers and clinicians to help them deliver fast, reliable and accurate diagnosis at the point-of-care. Mologic’s founder, Professor Paul Davis, was the originator of the Clearblue pregnancy test that was launched in 1988 as the world’s first commercial application of lateral flow technology. The creativity, insight and knowledge that led to that ground-breaking invention has guided Mologic since its formation in 2003.

Proton Therapy Opens at Sibley Memorial Hospital, a Member of Johns Hopkins Medicine, US top ranked healthcare institution

Proton Therapy Opens at Sibley Memorial Hospital

Hitachi, Ltd announced that Hitachi has provided its advanced proton therapy system to Sibley Memorial Hospital (Washington DC, US),a member of Johns Hopkins Medicine (Maryland, US), and it has started treatment on October 25, 2019.On October 28, an opening ceremony at Sibley Memorial Hospital was held.The proton therapy system installed at Sibley includes spot scanning technology that sends a the rapeuticproton beam precisely conforming to the shape of the target tumor. It has three rotating gantry treatment rooms and one fixed beam research room.

This is the first Hitachi system in the US with Real-time Gated Proton Therapy capability, which allows real-time beam irradiation to the tumor while compensating for movement associated with respiration. Johns Hopkins Medicine, based in Baltimore, Maryland, US, is a world-class hospital focusing on medical research and clinical care. Johns Hopkins Hospital has maintained its position as one of top hospitals in U.S. News & World Report rankings for decades.

Sibley Memorial Hospital, an affiliate of Johns Hopkins Medicine, provides cancer care from  the  world-renowned Johns  Hopkins  Sidney  Kimmel  Comprehensive  Cancer Center which also has one of the most successful cancer research programs in the world. Hitachi has been proactively promoting particle therapy system business worldwide, supplying  world-class  facilities  with  its  highly  reliable  and  proven  particletherapy systems, which have treated more than 60,000 patients. Hitachi will provide system and services, including single room solution in realizing installation in urban limited areas and hybrid system combined with capability of generating both proton and heavy ion in one accelerator, to meet all customer needs.

Hitachi  will  continue  to  accelerate  the  globalization  of  its  particle  therapy  system business and contribute to cancer treatment around the world.Note: *U.S. News & World Report releases its Best Hospitals rankings in the country every year.Overview of Particle TherapyParticle Therapy is an advanced type of cancer radiotherapy. Protons extracted from hydrogen atoms, or carbon ions are accelerated up to 70% of the speed of light.

This energy  is  concentrated  directly  on  the  tumor  while  minimizing  radiation  dose  to surrounding healthy tissue. Particle therapy improves the quality of life for cancer patients since the patient experiences no pain during treatment and the procedure has very few side effects compared to that of traditional radiotherapy. In most cases, patients can continue with their normal daily activities while undergoing treatment.

About Hitachi, Ltd.
Hitachi,  Ltd ,  headquartered  in  Tokyo,  Japan,  is  focusing  on  Social Innovation Business combining its operational technology, information technology and products. The company’s consolidated revenues for fiscal 2018 (ended March 31, 2019) totaled 9,480.6 billion yen ($85.4 billion), and the company has approximately 296,000 employees worldwide. Hitachi delivers digital solutions utilizing Lumada in five sectors  including  Mobility,  Smart  Life,  Industry,  Energy  and  IT,  to  increase  our customer’s social, environmental and economic value. For more information on Hitachi please visit the company’s website at https://www.hitachi.com

The American Academy of Anti-Aging Medicine Looks Ahead Towards the 27th Annual World Congress

The American Academy of Anti-Aging Medicine Looks Ahead Towards the 27th Annual World Congress

The American Academy of Anti-Aging Medicine (A4M) is gearing up for the 27th Annual World Congress taking place in Las Vegas from December 13-15. As the largest event in Anti-Aging medicine worldwide, the conference is set to host thousands of the industry’s leading clinical professionals including renowned practitioners, innovative companies, and like-minded partner organizations.

The annual conference boasts an extensive agenda featuring five pre-conference workshops, a brand new Aesthetics Symposium, the annual MedTech Impact on Wellness symposium, an extensive variety of session topics, and a faculty panel consisting of the foremost clinical experts and thought leaders in Anti-Aging and Integrative medicine. Rooted in a forward-focused mission to redefine modern medicine, this conference will disseminate the most valuable knowledge, recent updates, and clinical expertise within Anti-Aging medicine available.

The event will begin with five pre-conference workshops covering a broad range of topics. Led by industry’s experts, pre-conference attendees will gain valuable and in-depth knowledge during workshops focused on Precision Medicine and Diabetes, Hormones and Chronic Disease, Peptides and Aging, Stem Cells, and Practice Management. In placing an emphasis on equipping practitioners with the advanced capabilities to improve clinical outcomes and enhance practice efficiency, these pre-conference workshops will offer clinicians the opportunity to begin the conference with actionable knowledge ready to be integrated into practice.

This year’s conference will feature three keynote speakers from a diverse range of clinical backgrounds— but each serving, in their own respective right, as a pioneering leader in a new and transformative form of healthcare. On the first day of the conference, attendees will hear Dr. Anna Lembke, MD share her keynote presentation titled: “The Opioid Epidemic: From Freud to Fentanyl.” Currently serving as the program director for the Stanford Addiction Medicine Fellowship, psychiatrist Dr. Lembke, was one of the first in the medical community to sound the alarm regarding the epidemic of overprescribing opioids. During the second day of the conference, attendees will learn from Dr. Robert Pearl MD–the former CEO of Kaiser Permanente and longstanding prominent authority on healthcare culture and delivery. Dr. Pearl will provide listeners with valuable and timely insight during his presentation on “Fixing American Healthcare: Structure, Reimbursement, and an Aging Population.” On the third day of the conference, Dr Louise Aronson, MD will take the stage to share her presentation titled “Future of Elderhood: Life, Vitality, and Transformation.”

A Harvard graduate, leading geriatrician, Professor of Medicine at the University of California, San Francisco (UCSF), and the author of the New York Times bestseller Elderhood: Redefining Aging, Transforming Medicine, and Reimagining, Dr.Aronson is a well-respected thought leader and practitioner regarding geriatric care and the process of aging. In questioning the status quo and pushing well-beyond traditional standards of medicine, these speakers will help lead attendees in envisioning and ultimately practicing a redefined form of medicine.

The conference’s newest educational offering, The Aesthetics Symposium, will provide in-depth understanding surrounding one of the most quickly expanding industries: aesthetic medicine. Hosted in partnership with the South Beach Symposium and led by aesthetic medicine experts Mark S. Nestor, MD, PhD, and Michael H. Gold, MD and anti-aging thought leader, Patrick Bitter, MD, The Aesthetic Symposium will provide an in-depth and comprehensive examination of the latest advancements, novel technology, and market knowledge available within modern aesthetic medicine.

The conference will additionally feature the MedTech Impact on Wellness symposium, an annual educational symposium centered upon the emerging clinical value in digital health. The event hosts digital health stakeholders, clinicians, health IT executives, entrepreneurs, and researchers to promote the development of patient-centered medical technology. Speakers at this year’s symposium will cover a diverse range of topics including application interoperability, telemedicine, the role of artificial intelligence in clinical decision making, and data-driven healthcare among various others.

Throughout the entirety of the conference, attendees will break off into sessions highlighting an extensive variety of topics including targeted approaches to brain and pain, CBD, intermittent fasting, oncological care, gut health and much more. With over 75 educational sessions, 18 learning tracks, 9 Professional Medical Education workshops, and 10 Product Theater presentations, attendees will be given the opportunity to customize their conference experience to best suit their clinical needs and interests.

The conference will additionally provide attendees access to an Exhibit Hall that will host over 400 companies, showcasing key therapeutic products, devices, and services in Integrative, Anti-Aging, & Aesthetic Medicine: including pharmaceutical products and diagnostic testing, CBD, nutraceuticals and cosmeceuticals, digital health devices, and the most recently available medical technologies. Collectively, the companies will offer attendees the opportunity to leave home with valuable resources to integrate into practices across the globe.

1...668669670...1,125Page 669 of 1,125

About us

Hospital & healthcare Management is a leading B2B arena designed for the healthcare sector, it allow members to reach both ends of the healthcare facility procurement chain. . . Read More

Subscribe us

System

Resources

Archive Links

Subscribe

Copyright © 2008 - 2026 Hospital & Healthcare Management. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »